CompletedPhase 2

Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer

Slovenia57 participantsStarted 2004-06

Plain-language summary

A Phase II study aimed to evaluate the efficacy and toxicity of preoperative chemoradiotherapy with capecitabine in locally advanced resectable rectal cancer.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * histologically verified adenocarcinoma of the rectum, * resectable clinical stage II or III (IUCC TNM classification 2002); * no prior radiotherapy and/or chemotherapy; * World Health Organisation (WHO) performance status \< 2; * age at diagnosis of 18 or older; * and adequate bone marrow, liver, renal and cardiac function (no history of ischemic heart disease). Exclusion Criteria: * A history of prior malignancy other than non-melanoma skin cancer or in situ carcinoma of the cervix

What they're measuring

complete pathological remission rate

Timeframe: 9 weeks

Trial details

NCT IDNCT01152710

SponsorInstitute of Oncology Ljubljana

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2006-03

View on ClinicalTrials.gov More Resectable Rectal Cancer Clinical Stage II and III trials